Searches / Journal Of The Formosan Medical Association = Taiwan Yi Zhi[JOURNAL]

Journal Of The Formosan Medical Association = Taiwan Yi Zhi[JOURNAL]

Sun 200 papers
RSS

Comment on "Automated liver volumetry and hepatic steatosis quantification with magnetic resonance imaging proton density fat fraction".

Anand VV, Namdar PK, Baalann KP

J Formos Med Assoc · 2026 May · PMID 42191492 · Publisher ↗

Abstract loading — click title to view on PubMed.

Comment on "Hepatitis C micro-elimination in people who inject drugs: Incarcerated or methadone maintenance therapy in Taiwan".

Sarath Kumar SJ, Tangri S, Tangri P

J Formos Med Assoc · 2026 May · PMID 42191491 · Publisher ↗

Abstract loading — click title to view on PubMed.

Comment on "Operationalizing vascular frailty: Structural and functional vascular ageing as determinants of geriatric phenotypes".

Alik Kumar L

J Formos Med Assoc · 2026 May · PMID 42185175 · Publisher ↗

Abstract loading — click title to view on PubMed.

Comment on "integrating machine learning into fracture liaison services: Toward precision risk stratification in osteoporosis care".

Dattatreya Goud M

J Formos Med Assoc · 2026 May · PMID 42185174 · Publisher ↗

Abstract loading — click title to view on PubMed.

Further considerations on the incremental value of CONUT score in surgically treated head and neck cancer.

Wang X, Lyu Q

J Formos Med Assoc · 2026 May · PMID 42185173 · Publisher ↗

Abstract loading — click title to view on PubMed.

Revisiting a cuproptosis-related lncRNA prognostic model in breast cancer: considerations on biological specificity and clinical applicability.

Wang W, Jiang W, Wei L … +1 more , Gao X

J Formos Med Assoc · 2026 May · PMID 42185172 · Publisher ↗

Abstract loading — click title to view on PubMed.

Bridging genetic-environmental features and intelligent exercise rehabilitation in Alzheimer's disease classification.

Yang A, Xu H, Yang J … +1 more , Wang T

J Formos Med Assoc · 2026 May · PMID 42185171 · Publisher ↗

Abstract loading — click title to view on PubMed.

Response to comment on "Graves' disease-associated dopaminergic system dysfunction and its effects on striatocortical functional connectivity and cognitive function".

Abdullah M, Lin SH, Huang LC … +1 more , Yang YK

J Formos Med Assoc · 2026 May · PMID 42177161 · Publisher ↗

Abstract loading — click title to view on PubMed.

Response to "Platelet rich plasma in adhesive capsulitis from symptomatic relief to tissue restoration and inflammatory control".

Yang SM, Hsiao MY

J Formos Med Assoc · 2026 May · PMID 42177159 · Publisher ↗

Abstract loading — click title to view on PubMed.

Rethinking thyroid dysfunction after proton and photon radiotherapy for head and neck cancer.

Liao J, Wu H, Hu L … +1 more , Li S

J Formos Med Assoc · 2026 May · PMID 42173787 · Publisher ↗

Abstract loading — click title to view on PubMed.

Conventional DVH metrics may not fully explain hypothyroidism risk after IMPT.

Li Y, Wang M

J Formos Med Assoc · 2026 May · PMID 42173786 · Publisher ↗

Abstract loading — click title to view on PubMed.

SGLT2 inhibitors and geriatric syndromes in older adults with type 2 diabetes: A real-world cohort study.

Lee CY, Fang TJ, Jen CH … +2 more , Huang HC, Chuang YS

J Formos Med Assoc · 2026 May · PMID 42173784 · Publisher ↗

BACKGROUND: Sodium-glucose cotransporter-2 (SGLT2) inhibitors provide cardiorenal benefits in type 2 diabetes mellitus (T2DM), but concerns persist regarding potential exacerbation of geriatric syndromes through osmotic... BACKGROUND: Sodium-glucose cotransporter-2 (SGLT2) inhibitors provide cardiorenal benefits in type 2 diabetes mellitus (T2DM), but concerns persist regarding potential exacerbation of geriatric syndromes through osmotic diuresis, volume depletion, and catabolic weight loss in older adults. This study evaluated the association between SGLT2 inhibitors and geriatric syndromes, all-cause hospitalization, and all-cause mortality. METHODS: A cohort study was conducted using data from TriNetX global health research network between January 1, 2014 to December 31, 2020. Adults aged ≥65 years with T2DM newly initiated on SGLT2 inhibitors or dipeptidyl peptidase-4 (DPP-4) inhibitors were included. Propensity score matching (1:1) was performed to minimize confounding and reduce bias from unequal distribution of baseline characteristics and treatment effects. Primary outcomes were incident geriatric syndromes; secondary outcomes were all-cause hospitalization and mortality at 6 months, 1 year, and 5 years. RESULTS: After matching, 42,440 individuals were included in each group (mean age 71.4 years, 60% male). SGLT2 inhibitor initiation was associated with lower risks of multiple geriatric syndromes, including delirium, cognitive impairment, and pressure injuries. Five-year hazard ratios were 0.81 (95% CI: 0.78-0.83) for all-cause hospitalization and 0.65 (95% CI: 0.62-0.69) for all-cause mortality. Findings remained consistent across subgroups stratified by age, sex, glycated hemoglobin (HbA1c) control, heart disease, and renal function. CONCLUSION: In older adults with T2DM, SGLT2 inhibitor use was not associated with increased geriatric syndromes but rather with lower risks of geriatric outcomes, all-cause hospitalization, and all-cause mortality, supporting their use within comprehensive geriatric assessment frameworks.

Response to comment on "Considering the unmeasured impact of 5-fluorouracil dose intensity in the interpretation of optimal initial relative dose intensity of modified FOLFIRINOX".

Ho IW, Li CP, Yang SH … +12 more , Wang HT, Lin CY, Su YY, Ho CL, Chou WC, Chiu TJ, Shih YH, Feng YH, Chang YS, Hung CC, Chiu CF, Bai LY

J Formos Med Assoc · 2026 May · PMID 42173783 · Publisher ↗

Abstract loading — click title to view on PubMed.

← Prev Page 5 of 10 Next →

About

Frequency
Sun
Papers found
200
RSS feed
Subscribe